Bellicum Pharmaceuticals (BLCM) Trading Down 10%

Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) shares traded down 10% during trading on Thursday . The company traded as low as $3.61 and last traded at $3.62. 524,861 shares were traded during trading, an increase of 39% from the average session volume of 377,737 shares. The stock had previously closed at $4.02.

A number of research firms have recently issued reports on BLCM. Zacks Investment Research cut shares of Bellicum Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, January 29th. ValuEngine upgraded shares of Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Bellicum Pharmaceuticals has a consensus rating of “Hold” and an average price target of $12.28.

The stock has a market cap of $178.61 million, a P/E ratio of -1.48 and a beta of 1.57. The company has a debt-to-equity ratio of 0.52, a quick ratio of 6.03 and a current ratio of 6.03.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its quarterly earnings data on Tuesday, March 12th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.05). The company had revenue of $0.31 million during the quarter, compared to the consensus estimate of $0.18 million. Bellicum Pharmaceuticals had a negative net margin of 8,753.21% and a negative return on equity of 115.46%. Equities analysts predict that Bellicum Pharmaceuticals Inc will post -2.09 EPS for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Deutsche Bank AG lifted its position in Bellicum Pharmaceuticals by 152.3% in the 4th quarter. Deutsche Bank AG now owns 330,195 shares of the biopharmaceutical company’s stock valued at $963,000 after acquiring an additional 199,317 shares in the last quarter. Geode Capital Management LLC lifted its position in Bellicum Pharmaceuticals by 19.9% in the 4th quarter. Geode Capital Management LLC now owns 509,310 shares of the biopharmaceutical company’s stock valued at $1,487,000 after acquiring an additional 84,517 shares in the last quarter. Jane Street Group LLC bought a new stake in Bellicum Pharmaceuticals in the 4th quarter valued at $48,000. Paloma Partners Management Co bought a new stake in Bellicum Pharmaceuticals in the 4th quarter valued at $65,000. Finally, Bank of America Corp DE lifted its position in Bellicum Pharmaceuticals by 1,394.2% in the 4th quarter. Bank of America Corp DE now owns 134,777 shares of the biopharmaceutical company’s stock valued at $393,000 after acquiring an additional 125,757 shares in the last quarter. 53.07% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Bellicum Pharmaceuticals (BLCM) Trading Down 10%” was first published by WKRB News and is owned by of WKRB News. If you are reading this story on another site, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The legal version of this story can be viewed at https://www.wkrb13.com/2019/04/11/bellicum-pharmaceuticals-blcm-trading-down-10.html.

Bellicum Pharmaceuticals Company Profile (NASDAQ:BLCM)

Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.

See Also: Trading Strategy

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.